ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Resonance Health's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 15.37%.
As of today (2026-06-24), Resonance Health's WACC % is 12.41%. Resonance Health's ROC % is 4.57% (calculated using TTM income statement data).
Resonance Health earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Resonance Health (ASX:RHT) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Resonance Health's WACC % is 12.41%. Resonance Health's ROC % is 4.57% (calculated using TTM income statement data).
Resonance Health earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Resonance Health ROC % Related Terms
Resonance Health ROC % Historical Data
* Premium members only.
The historical data trend for Resonance Health's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a ROC % of 15.37% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Resonance Health and its competitors.
Is Resonance Health's ROC % too high?
Resonance Health's current ROC % is 15.37%. The Healthcare Providers & Services industry median ROC % is 3.06. Resonance Health's value of 15.37% is 402.3% above this industry median.
How does Resonance Health's ROC % compare to VEEV and BTSG?
Resonance Health's ROC % of 15.37% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROC % is 3.06. Resonance Health's value of 15.37% is 402.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Healthcare Providers & Services company?
The median ROC % among Healthcare Providers & Services companies is 3.06, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current ROC % of 15.37% is 402.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median ROC % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current ROC % is 15.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current ROC % is 15.37% and 402.3% above the Healthcare Providers & Services industry median of 3.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current ROC % is 15.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 